<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19571" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cisplatin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gold</surname>
            <given-names>Joann M.</given-names>
          </name>
          <aff>University of Tennessee Health Science Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Raja</surname>
            <given-names>Avais</given-names>
          </name>
          <aff>University of Western States, Portland, Oregon</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joann Gold declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Avais Raja declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19571.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications. This activity reviews the indications, action, and contraindications for cisplatinum as a valuable agent in treating malignancy. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for the interprofessional oncology team members in the care of patients with malignancy treated with this agent.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of cisplatin.</p></list-item><list-item><p>Describe the adverse effects associated with cisplatin therapy.</p></list-item><list-item><p>Review the appropriate monitoring necessary with cisplatin therapy.</p></list-item><list-item><p>Outline how collaboration and coordination among the interprofessional team can enhance patient care when dosing and monitoring cisplatin to improve patient outcomes for patients receiving antineoplastic therapy with cisplatin.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19571&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19571">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19571.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Cisplatin is an antineoplastic agent that came into use in the late 1970s. Cisplatin, while highly toxic, is one of the most heavily utilized chemotherapeutic agents for hematologic and solid tumor malignancies. It can be used as a single-agent or combination therapy for induction and neoadjuvant therapy.&#x000a0;</p>
        <p>
<bold>Adult Indications</bold>
</p>
        <p>Cisplatin is FDA approved for the treatment of advanced ovarian cancer, testicular cancer, and bladder carcinoma.<xref ref-type="bibr" rid="article-19571.r1">[1]</xref><xref ref-type="bibr" rid="article-19571.r2">[2]</xref>&#x000a0;However, clinicians frequently use cisplatin off-label for a number of other malignancies, as detailed below, when the benefits may outweigh the risks of adverse drug effects.&#x000a0;</p>
        <p>Malignancies that predominate in women, such as breast cancer, cervical and endometrial carcinoma, and gestational trophoblastic neoplasia, sometimes receive treatment with cisplatin in combination with other medications such as taxane derivatives, 5-FU, and doxorubicin.<xref ref-type="bibr" rid="article-19571.r3">[3]</xref><xref ref-type="bibr" rid="article-19571.r4">[4]</xref><xref ref-type="bibr" rid="article-19571.r5">[5]</xref>&#x000a0;While hormone-sensitive and Her2neu-positive tumors may respond well to targeted therapy, cisplatin is also useful in treating triple-negative breast cancer as a single agent neoadjuvant therapy.<xref ref-type="bibr" rid="article-19571.r3">[3]</xref></p>
        <p>Gastrointestinal malignancies such as esophageal, gastric, and hepatobiliary cancer have also been treated off-label with this medication and radiation.<xref ref-type="bibr" rid="article-19571.r6">[6]</xref><xref ref-type="bibr" rid="article-19571.r7">[7]</xref><xref ref-type="bibr" rid="article-19571.r8">[8]</xref>&#x000a0;Advanced cervical cancer is another off-label indication. Lung cancer, both small and non-small cells, can be treated off-label&#x000a0;using&#x000a0;etoposide and cisplatin combination therapy.<xref ref-type="bibr" rid="article-19571.r9">[9]</xref><xref ref-type="bibr" rid="article-19571.r10">[10]</xref></p>
        <p>Other off-label uses include treatment for metastatic, advanced, and refractory cancers; this includes the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, penile cancer, thymoma, head and neck cancers, osteosarcoma, multiple myeloma, and mesothelioma.<xref ref-type="bibr" rid="article-19571.r11">[11]</xref><xref ref-type="bibr" rid="article-19571.r12">[12]</xref><xref ref-type="bibr" rid="article-19571.r13">[13]</xref></p>
        <p>
<bold>Pediatric Indications</bold>
</p>
        <p>Cisplatin has&#x000a0;no approved indications for treatment in children. When utilized off-label, its indications are for historically aggressive tumors.<xref ref-type="bibr" rid="article-19571.r14">[14]</xref><xref ref-type="bibr" rid="article-19571.r15">[15]</xref> It is sometimes useful in treating germ cell tumors, hepatoblastoma, medulloblastoma, neuroblastoma, and osteosarcoma, but universal guidelines on dosing and duration are not available.<xref ref-type="bibr" rid="article-19571.r16">[16]</xref><xref ref-type="bibr" rid="article-19571.r17">[17]</xref><xref ref-type="bibr" rid="article-19571.r18">[18]</xref></p>
      </sec>
      <sec id="article-19571.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cisplatin acts via non-cell cycle-specific cytotoxicity, which is achieved through the covalent binding of platinum to the purine bases guanine and adenine. This covalent binding leads to intra-strand and inter-strand crosslinks causing subsequent strand breaks. While DNA repair mechanisms are at play, cells often undergo apoptotic or non-apoptotic cell death due to remnant damaged DNA, RNA, and proteins.<xref ref-type="bibr" rid="article-19571.r19">[19]</xref> Cisplatin chemotherapy is particularly effective at targeting rapidly dividing cells, as appreciated in rapidly growing malignant tumors.<xref ref-type="bibr" rid="article-19571.r20">[20]</xref> Theoretically, cisplatin may not be as useful for slow-growing tumors.</p>
        <p>The drug is primarily excreted in the urine, with 10% in the bile. Its initial half-life is approximately 20 to 30 minutes, with a terminal half-life of 24 hours. ALbumin-bound platinum undergoes slow administration of minimally five days.</p>
      </sec>
      <sec id="article-19571.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Cisplatin can be administered as an injectable agent both intravenously and as an intra-arterial agent.<xref ref-type="bibr" rid="article-19571.r21">[21]</xref> Cisplatin can also be utilized as an intraperitoneal agent, as seen in treating carcinomatosis and primary peritoneal carcinoma. However, this use is not FDA approved and is &#x0201c;off-label&#x0201d; use.<xref ref-type="bibr" rid="article-19571.r22">[22]</xref> Before administration, the patient must achieve adequate hydration and maintain hydration and urinary output 24 hours after administration. Anti-emetic agents can be utilized prophylactically to prevent nausea and vomiting.<xref ref-type="bibr" rid="article-19571.r23">[23]</xref></p>
        <p>
<bold>Approved Adult Dosing Regimens</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Advanced testicular cancer: 20 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.</p>
          </list-item>
          <list-item>
            <p>Advanced bladder cancer:&#x000a0;50 to 70 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.</p>
          </list-item>
          <list-item>
            <p>Advanced ovarian cancer:&#x000a0;100 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.</p>
          </list-item>
        </list>
        <p>Cisplatin can be used as monotherapy or as part of a multi-drug regimen. Patients should have proper hydration while monitoring urine output before, during, and for 24 hours following administration.</p>
        <p>
<bold>Renal Dose Adjustments</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Creatinine clearance between 10 and 50: decrease dose by 25%</p>
          </list-item>
          <list-item>
            <p>Creatinine clearance below 10: decrease dose by 50%</p>
          </list-item>
          <list-item>
            <p>Hemodialysis: Decrease the dose by 50% with no supplement; administer&#x000a0;after&#x000a0;dialysis on dialysis days with no supplement</p>
          </list-item>
          <list-item>
            <p>Peritoneal dialysis:&#x000a0;Decrease the dose by 50% with no supplement</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19571.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Extravasation - If extravasation is suspected, the infusion should stop immediately. Any obvious fluid collection should&#x000a0;be aspirated, and the extremity elevated. The antidote, sodium thiosulfate, should be administered.<xref ref-type="bibr" rid="article-19571.r24">[24]</xref></p>
        <p>Secondary malignancy - Leukemia is the most common secondary malignancy after treatment with cisplatin, and this typically occurs many years after completion of treatment.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r26">[26]</xref></p>
        <p>Tumor lysis syndrome can occur after treatment with many chemotherapeutic agents and manifest as hyperuricemia, alteration in hemodynamics, hyperkalemia, and azotemia. Uric acid-reducing treatments may be necessary.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r27">[27]</xref></p>
        <p>
<bold>Common Side Effects</bold>
<xref ref-type="bibr" rid="article-19571.r27">[27]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diarrhea</p>
          </list-item>
          <list-item>
            <p>Temporary hair loss</p>
          </list-item>
          <list-item>
            <p>Loss in the ability to taste food</p>
          </list-item>
          <list-item>
            <p>Hiccups</p>
          </list-item>
          <list-item>
            <p>Dry mouth</p>
          </list-item>
          <list-item>
            <p>Dark urine</p>
          </list-item>
          <list-item>
            <p>Decreased sweating</p>
          </list-item>
          <list-item>
            <p>Dry skin</p>
          </list-item>
          <list-item>
            <p>Dehydration</p>
          </list-item>
        </list>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Caution is necessary when administering cisplatin with any of the following medications. Most drug interactions result in cumulative and dose-dependent hematologic, renal, and neurotoxic effects. Due to cumulative myelosuppression, cisplatin should also not be used concurrently with immunosuppressive medications.<xref ref-type="bibr" rid="article-19571.r28">[28]</xref><xref ref-type="bibr" rid="article-19571.r29">[29]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Alpha-lipoic acid</p>
          </list-item>
          <list-item>
            <p>Aminoglycosides</p>
          </list-item>
          <list-item>
            <p>Baricitinib</p>
          </list-item>
          <list-item>
            <p>BCG</p>
          </list-item>
          <list-item>
            <p>Chloramphenicol</p>
          </list-item>
          <list-item>
            <p>Clozapine</p>
          </list-item>
          <list-item>
            <p>Deferiprone</p>
          </list-item>
          <list-item>
            <p>Denosumab</p>
          </list-item>
          <list-item>
            <p>Dipyrone</p>
          </list-item>
          <list-item>
            <p>Echinacea</p>
          </list-item>
          <list-item>
            <p>Fosphenytoin</p>
          </list-item>
          <list-item>
            <p>Leflunomide</p>
          </list-item>
          <list-item>
            <p>Lenogristim</p>
          </list-item>
          <list-item>
            <p>Lipefilgrastim</p>
          </list-item>
          <list-item>
            <p>Natalizumab</p>
          </list-item>
          <list-item>
            <p>Nivolumab</p>
          </list-item>
          <list-item>
            <p>Ocrelizumab</p>
          </list-item>
          <list-item>
            <p>Palifermin</p>
          </list-item>
          <list-item>
            <p>Pidotimod</p>
          </list-item>
          <list-item>
            <p>Pimecrolimus</p>
          </list-item>
          <list-item>
            <p>Promazine</p>
          </list-item>
          <list-item>
            <p>Roflumilast</p>
          </list-item>
          <list-item>
            <p>Siponimod</p>
          </list-item>
          <list-item>
            <p>Sipuleleucel-T</p>
          </list-item>
          <list-item>
            <p>Tacrolimus</p>
          </list-item>
          <list-item>
            <p>Taxane derivatives</p>
          </list-item>
          <list-item>
            <p>Tertomotide</p>
          </list-item>
          <list-item>
            <p>Topotecan</p>
          </list-item>
          <list-item>
            <p>Trastuzumab</p>
          </list-item>
          <list-item>
            <p>Vaccinations</p>
          </list-item>
          <list-item>
            <p>Vinorelbine</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-19571.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There are few absolute contraindications for cisplatin use for the treatment of malignancies. Severe hypersensitivity to cisplatin or platinum compounds would preclude its administration;&#x000a0;cisplatin is contraindicated in patients who have had severe hypersensitivity reactions, and rechallenge is not a recommendation.</p>
        <p>Cisplatin has been shown to cross the placenta and may cause fetal harm.<xref ref-type="bibr" rid="article-19571.r30">[30]</xref><xref ref-type="bibr" rid="article-19571.r31">[31]</xref>&#x000a0;Women of reproductive age should use reliable contraception during treatment and up to a year from the final treatment date. Cisplatin is also present in the breastmilk of lactating women on a&#x000a0;cisplatin regimen.<xref ref-type="bibr" rid="article-19571.r32">[32]</xref> Breastfeeding is not recommended during treatment.<xref ref-type="bibr" rid="article-19571.r32">[32]</xref>&#x000a0;If hypersensitivity occurs, the provider should discontinue cisplatin immediately.<xref ref-type="bibr" rid="article-19571.r33">[33]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-19571.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>A pregnancy test is necessary to determine pregnancy status in female patients before administering cisplatin.<xref ref-type="bibr" rid="article-19571.r30">[30]</xref></p>
        <p>Hematologic - The clinician should order a complete blood count (CBC) before initiating treatment and before each subsequent treatment course.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref></p>
        <p>Renal function - Serum creatinine, blood urea nitrogen, creatinine clearance, and electrolytes (Na, K, Ca, Mg) require an assessment before treatment administration.<xref ref-type="bibr" rid="article-19571.r34">[34]</xref><xref ref-type="bibr" rid="article-19571.r35">[35]</xref></p>
        <p>Hearing and vestibular - Audiometric testing should be ordered in pediatric patients to determine baseline and before each administration. After discontinuing therapy, audiometric testing should continue for several years.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r35">[35]</xref><xref ref-type="bibr" rid="article-19571.r36">[36]</xref></p>
        <p>Infusion - The infusion site should be assessed before, during, and after drug administration to assess for infection and extravasation. The patient should be monitored clinically for complications of administration.<xref ref-type="bibr" rid="article-19571.r24">[24]</xref><xref ref-type="bibr" rid="article-19571.r37">[37]</xref><xref ref-type="bibr" rid="article-19571.r38">[38]</xref></p>
        <p>One also has to monitor the patient for neuropathy, ocular changes, and signs of systemic infection.</p>
      </sec>
      <sec id="article-19571.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>CIsplatin has several black box warnings, including nephrotoxicity, peripheral neuropathy, severe nausea and vomiting, and myelosupression.</p>
        <p>Gastrointestinal toxicity - Nausea and vomiting are dose-related side effects that can be severe and lead to metabolic derangements; this can persist for up to 1 week after administration. The strong recommendation is for prophylactic treatment with antiemetic agents.<xref ref-type="bibr" rid="article-19571.r39">[39]</xref><xref ref-type="bibr" rid="article-19571.r25">[25]</xref></p>
        <p>Myelosuppression - The chief concern with myelosuppression secondary to cisplatin use is the morbidity and mortality associated with infection. Monitor CBC and frequently assess for signs of infection. High clinical suspicion is necessary for infection and warrants a full workup.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref>&#x000a0;Hematologic toxicity may require total treatment interruption. Often it will require dose modification if treatment is to continue.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref></p>
        <p>Neurotoxicity -&#x000a0;Cisplatin is a dose-dependent neurotoxin.<xref ref-type="bibr" rid="article-19571.r40">[40]</xref> Dose-related neurotoxicity most commonly manifests as peripheral neuropathy. This neuropathy may progress after discontinuation and, in some cases, might be irreversible.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r41">[41]</xref>&#x000a0;While dosage may require alteration in the face of neuropathy,&#x000a0;high-grade peripheral neuropathy may require total treatment discontinuation.&#x000a0;</p>
        <p>Nephrotoxicity - Severe renal toxicity, including acute renal failure, may occur with Cisplatin administration. These effects are cumulative and dose-related. Pretreatment hydration plays a significant role in preventing renal toxicity.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r34">[34]</xref><xref ref-type="bibr" rid="article-19571.r35">[35]</xref> The dose of cisplatin may require adjustment based on renal function with close monitoring of the glomerular filtration rate (GFR).<xref ref-type="bibr" rid="article-19571.r33">[33]</xref></p>
        <p>Ocular toxicity/retinopathy - These adverse effects can manifest in a variety of ways, from loss of color discrimination to cortical blindness. Improvement usually occurs after discontinuation of cisplatin, and in some cases, total recovery may be possible.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r42">[42]</xref></p>
        <p>Ototoxicity - Monitoring for ototoxicity includes assessing the patient for ringing in the ears, high-frequency hearing loss, and decreased ability to follow conversations. Deafness has been reported but is not a common effect of cisplatin use. Loss of hearing acuity can be detrimental to language development in pediatric populations.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref><xref ref-type="bibr" rid="article-19571.r35">[35]</xref></p>
        <p>Gonadotoxicity - Cisplatin is toxic to the gonads; it can cause impairment of spermatogenesis and dose-dependent ovarian failure leading to premature menopause.<xref ref-type="bibr" rid="article-19571.r25">[25]</xref></p>
      </sec>
      <sec id="article-19571.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional collaboration and care coordination between physicians (particularly oncology specialists), mid-level practitioners, nursing staff, pharmacists, and other healthcare providers enhance team performance and patient outcomes.<xref ref-type="bibr" rid="article-19571.r43">[43]</xref> Working as a team while caring for patients undergoing treatment with cisplatin is of great importance.<xref ref-type="bibr" rid="article-19571.r44">[44]</xref> As a team, monitoring for side effects and toxicity can be more efficient with&#x000a0;fewer poor outcomes and earlier intervention.<xref ref-type="bibr" rid="article-19571.r45">[45]</xref><xref ref-type="bibr" rid="article-19571.r44">[44]</xref>&#x000a0;</p>
        <p>Communication among healthcare professionals between various clinical disciplines is crucial. For example, any dose greater than 100 mg/m^2 for a single treatment course requires verification with the initial medication prescriber. The oncology specialty-trained pharmacist should also monitor for the extensive drug-drug interactions with cisplatin and promptly alert the ordering clinician upon finding any reason for concern.</p>
        <p>Nurses need to be aware of the importance of hydration and monitoring the site of IV infusion for extravasation. Also, all clinicians should monitor the patient for signs of infection, renal impairment, and the development of tumor lysis syndrome. Open communication between the interprofessional team is vital to prevent the adverse effects of this agent while optimizing its therapeutic effect, driving optimal patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-19571.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19571&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19571">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19571/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19571">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19571.s11">
        <title>References</title>
        <ref id="article-19571.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozols</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Bundy</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Clarke-Pearson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Mannel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>DeGeest</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hartenbach</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Baergen</surname>
                <given-names>R</given-names>
              </name>
              <collab>Gynecologic Oncology Group</collab>
            </person-group>
            <article-title>Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.</article-title>
            <source>J Clin Oncol</source>
            <year>2003</year>
            <month>Sep</month>
            <day>01</day>
            <volume>21</volume>
            <issue>17</issue>
            <fpage>3194</fpage>
            <page-range>3194-200</page-range>
            <pub-id pub-id-type="pmid">12860964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kondagunta</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Bacik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Donadio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bajorin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marion</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheinfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bosl</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Motzer</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.</article-title>
            <source>J Clin Oncol</source>
            <year>2005</year>
            <month>Sep</month>
            <day>20</day>
            <volume>23</volume>
            <issue>27</issue>
            <fpage>6549</fpage>
            <page-range>6549-55</page-range>
            <pub-id pub-id-type="pmid">16170162</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silver</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Eklund</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Szallasi</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Juul</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Leong</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Calogrias</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Buraimoh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fatima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gelman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Tung</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>De Nicolo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ganesan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miron</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Colin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sgroi</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ellisen</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Winer</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Garber</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.</article-title>
            <source>J Clin Oncol</source>
            <year>2010</year>
            <month>Mar</month>
            <day>01</day>
            <volume>28</volume>
            <issue>7</issue>
            <fpage>1145</fpage>
            <page-range>1145-53</page-range>
            <pub-id pub-id-type="pmid">20100965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitney</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Sause</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bundy</surname>
                <given-names>BN</given-names>
              </name>
              <name>
                <surname>Malfetano</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hannigan</surname>
                <given-names>EV</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Clarke-Pearson</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>SY</given-names>
              </name>
            </person-group>
            <article-title>Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.</article-title>
            <source>J Clin Oncol</source>
            <year>1999</year>
            <month>May</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>1339</fpage>
            <page-range>1339-48</page-range>
            <pub-id pub-id-type="pmid">10334517</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleming</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Brunetto</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Cella</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Look</surname>
                <given-names>KY</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Munkarah</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Kline</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burks</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Jun</month>
            <day>01</day>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>2159</fpage>
            <page-range>2159-66</page-range>
            <pub-id pub-id-type="pmid">15169803</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Starling</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iveson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nicolson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Coxon</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oates</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>AR</given-names>
              </name>
              <collab>Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom</collab>
            </person-group>
            <article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2008</year>
            <month>Jan</month>
            <day>03</day>
            <volume>358</volume>
            <issue>1</issue>
            <fpage>36</fpage>
            <page-range>36-46</page-range>
            <pub-id pub-id-type="pmid">18172173</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tepper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krasna</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Niedzwiecki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hollis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Goldberg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kiel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Willett</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sugarbaker</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.</article-title>
            <source>J Clin Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <day>01</day>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>1086</fpage>
            <page-range>1086-92</page-range>
            <pub-id pub-id-type="pmid">18309943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wasan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anthoney</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maraveyas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Madhusudan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iveson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Roughton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bridgewater</surname>
                <given-names>J</given-names>
              </name>
              <collab>ABC-02 Trial Investigators</collab>
            </person-group>
            <article-title>Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Apr</month>
            <day>08</day>
            <volume>362</volume>
            <issue>14</issue>
            <fpage>1273</fpage>
            <page-range>1273-81</page-range>
            <pub-id pub-id-type="pmid">20375404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wozniak</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Balcerzak</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Spiridonidis</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Albain</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gandara</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>RB</given-names>
              </name>
            </person-group>
            <article-title>Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.</article-title>
            <source>J Clin Oncol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>16</volume>
            <issue>7</issue>
            <fpage>2459</fpage>
            <page-range>2459-65</page-range>
            <pub-id pub-id-type="pmid">9667264</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Turrisi</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Blum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sause</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Livingston</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Komaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Aisner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Jan</month>
            <day>28</day>
            <volume>340</volume>
            <issue>4</issue>
            <fpage>265</fpage>
            <page-range>265-71</page-range>
            <pub-id pub-id-type="pmid">9920950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fornasiero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Daniele</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ghiotto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piazza</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiore-Donati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Calabr&#x000f3;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rea</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Fiorentino</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy for invasive thymoma. A 13-year experience.</article-title>
            <source>Cancer</source>
            <year>1991</year>
            <month>Jul</month>
            <day>01</day>
            <volume>68</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-3</page-range>
            <pub-id pub-id-type="pmid">2049749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velasquez</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Salvador</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fridrik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jagannath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hagemeister</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Redman</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).</article-title>
            <source>Blood</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>117</fpage>
            <page-range>117-22</page-range>
            <pub-id pub-id-type="pmid">3334893</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Velasquez</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tucker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hagemeister</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Swan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Romaguera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rubenstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cabanillas</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.</article-title>
            <source>J Clin Oncol</source>
            <year>1994</year>
            <month>Jun</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>1169</fpage>
            <page-range>1169-76</page-range>
            <pub-id pub-id-type="pmid">8201379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cushing</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giller</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cullen</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Marina</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Lauer</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Colombani</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rescorla</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Billmire</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Vinocur</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Perlman</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Castleberry</surname>
                <given-names>RP</given-names>
              </name>
              <collab>Pediatric Oncology Group 9049</collab>
              <collab>Children's Cancer Group 8882</collab>
            </person-group>
            <article-title>Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.</article-title>
            <source>J Clin Oncol</source>
            <year>2004</year>
            <month>Jul</month>
            <day>01</day>
            <volume>22</volume>
            <issue>13</issue>
            <fpage>2691</fpage>
            <page-range>2691-700</page-range>
            <pub-id pub-id-type="pmid">15226336</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Douglass</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cantor</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Glicksman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study.</article-title>
            <source>J Clin Oncol</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>96</fpage>
            <page-range>96-9</page-range>
            <pub-id pub-id-type="pmid">8380296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.</article-title>
            <source>Childs Nerv Syst</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>1851</fpage>
            <page-range>1851-8</page-range>
            <pub-id pub-id-type="pmid">23748464</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreissman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Seeger</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Matthay</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>London</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Sposto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grupp</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Haas-Kogan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Laquaglia</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Diller</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Buxton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Maris</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Reynolds</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Villablanca</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>999</fpage>
            <page-range>999-1008</page-range>
            <pub-id pub-id-type="pmid">23890779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marina</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Smeland</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bielack</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jovic</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krailo</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hook</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Arndt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>van den Berg</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brichard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KLB</given-names>
              </name>
              <name>
                <surname>Butterfass-Bahloul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Calaminus</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Daldrup-Link</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Eriksson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gebhardt</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Gelderblom</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gerss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Goldsby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Goorin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorlick</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Grier</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Hardes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hawkins</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Helmke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hogendoorn</surname>
                <given-names>PCW</given-names>
              </name>
              <name>
                <surname>Isakoff</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Janeway</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>J&#x000fc;rgens</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kager</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hne</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Leavey</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lessnick</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Mascarenhas</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Meyers</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Mottl</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nathrath</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Randall</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Reichardt</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Safwat</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>MCG</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Teot</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sydes</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Whelan</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>17</volume>
            <issue>10</issue>
            <fpage>1396</fpage>
            <page-range>1396-1408</page-range>
            <pub-id pub-id-type="pmid">27569442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riddell</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>Cisplatin and Oxaliplatin: Our Current Understanding of Their Actions.</article-title>
            <source>Met Ions Life Sci</source>
            <year>2018</year>
            <month>Feb</month>
            <day>05</day>
            <volume>18</volume>
            <pub-id pub-id-type="pmid">29394020</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aggarwal</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>A histochemical approach to the mechanism of action of cisplatin and its analogues.</article-title>
            <source>J Histochem Cytochem</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>41</volume>
            <issue>7</issue>
            <fpage>1053</fpage>
            <page-range>1053-73</page-range>
            <pub-id pub-id-type="pmid">8515048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Dwyer</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>SW</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics and administration of established platinum drugs.</article-title>
            <source>Drugs</source>
            <year>2000</year>
            <volume>59 Suppl 4</volume>
            <fpage>19</fpage>
            <page-range>19-27</page-range>
            <pub-id pub-id-type="pmid">10864227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armstrong</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Bundy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Baergen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lele</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Burger</surname>
                <given-names>RA</given-names>
              </name>
              <collab>Gynecologic Oncology Group</collab>
            </person-group>
            <article-title>Intraperitoneal cisplatin and paclitaxel in ovarian cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Jan</month>
            <day>05</day>
            <volume>354</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-43</page-range>
            <pub-id pub-id-type="pmid">16394300</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roila</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Molassiotis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herrstedt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aapro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gralla</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bruera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Clark-Snow</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Einhorn</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Feyer</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hesketh</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Jordan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Olver</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Roscoe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruhlmann</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Warr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>van der Wetering</surname>
                <given-names>M</given-names>
              </name>
              <collab>participants of the MASCC/ESMO Consensus Conference Copenhagen 2015</collab>
            </person-group>
            <article-title>2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients.</article-title>
            <source>Ann Oncol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>suppl 5</issue>
            <fpage>v119</fpage>
            <page-range>v119-v133</page-range>
            <pub-id pub-id-type="pmid">27664248</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ener</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Meglathery</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Styler</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Extravasation of systemic hemato-oncological therapies.</article-title>
            <source>Ann Oncol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>858</fpage>
            <page-range>858-62</page-range>
            <pub-id pub-id-type="pmid">15151940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barabas</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Milner</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lurie</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Cisplatin: a review of toxicities and therapeutic applications.</article-title>
            <source>Vet Comp Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-18</page-range>
            <pub-id pub-id-type="pmid">19178659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vezina</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gajjar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.</article-title>
            <source>Neuro Oncol</source>
            <year>2013</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-103</page-range>
            <pub-id pub-id-type="pmid">23099653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baeksgaard</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-92</page-range>
            <pub-id pub-id-type="pmid">12655435</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balis</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic drug interactions of commonly used anticancer drugs.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1986</year>
            <season>May-Jun</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>223</fpage>
            <page-range>223-35</page-range>
            <pub-id pub-id-type="pmid">2426030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Furue</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>[Drug interactions with anticancer agents].</article-title>
            <source>Gan To Kagaku Ryoho</source>
            <year>1985</year>
            <month>Dec</month>
            <volume>12</volume>
            <issue>12</issue>
            <fpage>2231</fpage>
            <page-range>2231-6</page-range>
            <pub-id pub-id-type="pmid">3907502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zheng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Taxanes in combination with platinum derivatives for the treatment of ovarian cancer&#x000a0;during pregnancy: A literature review&#x02029;.</article-title>
            <source>Int J Clin Pharmacol Ther</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>55</volume>
            <issue>9</issue>
            <fpage>753</fpage>
            <page-range>753-760</page-range>
            <pub-id pub-id-type="pmid">28737125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brewer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kueck</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Runowicz</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy in pregnancy.</article-title>
            <source>Clin Obstet Gynecol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>4</issue>
            <fpage>602</fpage>
            <page-range>602-18</page-range>
            <pub-id pub-id-type="pmid">22031250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <chapter-title>Cisplatin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Otani</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Platinum Chemotherapy Hypersensitivity: Prevalence and Management.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>663</fpage>
            <page-range>663-677</page-range>
            <pub-id pub-id-type="pmid">28965633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crona</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Faso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nishijima</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>McGraw</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Galsky</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Milowsky</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.</article-title>
            <source>Oncologist</source>
            <year>2017</year>
            <month>May</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>609</fpage>
            <page-range>609-619</page-range>
            <pub-id pub-id-type="pmid">28438887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karasawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Steyger</surname>
                <given-names>PS</given-names>
              </name>
            </person-group>
            <article-title>An integrated view of cisplatin-induced nephrotoxicity and ototoxicity.</article-title>
            <source>Toxicol Lett</source>
            <year>2015</year>
            <month>Sep</month>
            <day>17</day>
            <volume>237</volume>
            <issue>3</issue>
            <fpage>219</fpage>
            <page-range>219-27</page-range>
            <pub-id pub-id-type="pmid">26101797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brock</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Freyer</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Steyger</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Blakley</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Rassekh</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Fligor</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Rajput</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Neuwelt</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale.</article-title>
            <source>J Clin Oncol</source>
            <year>2012</year>
            <month>Jul</month>
            <day>01</day>
            <volume>30</volume>
            <issue>19</issue>
            <fpage>2408</fpage>
            <page-range>2408-17</page-range>
            <pub-id pub-id-type="pmid">22547603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>JX</given-names>
              </name>
              <name>
                <surname>Wan</surname>
                <given-names>XR</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>[Clinical analysis of hypersensitivity reaction of platinum in ovarian cancer and cervical cancer patients].</article-title>
            <source>Zhonghua Fu Chan Ke Za Zhi</source>
            <year>2016</year>
            <month>Nov</month>
            <day>25</day>
            <volume>51</volume>
            <issue>11</issue>
            <fpage>825</fpage>
            <page-range>825-831</page-range>
            <pub-id pub-id-type="pmid">27916065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Handa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kuroiwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miyano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kamei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sonou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murayama</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kato</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Assessment of Injection Site Reactions for Peripheral Intravenous Oxaliplatin Infusion and Potential Remedies.</article-title>
            <source>Gan To Kagaku Ryoho</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>8</issue>
            <fpage>985</fpage>
            <page-range>985-8</page-range>
            <pub-id pub-id-type="pmid">27539041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paw Cho Sing</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Flank</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holdsworth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Thackray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Freedman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Orsey</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Portwine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raybin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cabral</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dupuis</surname>
                <given-names>LL</given-names>
              </name>
            </person-group>
            <article-title>Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2019</year>
            <month>May</month>
            <volume>66</volume>
            <issue>5</issue>
            <fpage>e27646</fpage>
            <pub-id pub-id-type="pmid">30729654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Avan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Postma</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Ceresa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Avan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cavaletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Giovannetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Platinum-induced neurotoxicity and preventive strategies: past, present, and future.</article-title>
            <source>Oncologist</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>411</fpage>
            <page-range>411-32</page-range>
            <pub-id pub-id-type="pmid">25765877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albers</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Chaudhry</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Cavaletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Donehower</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing neuropathy caused by cisplatin and related compounds.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2014</year>
            <month>Mar</month>
            <day>31</day>
            <issue>3</issue>
            <fpage>CD005228</fpage>
            <pub-id pub-id-type="pmid">24687190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.</article-title>
            <source>Onco Targets Ther</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>1361</fpage>
            <page-range>1361-6</page-range>
            <pub-id pub-id-type="pmid">25114574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Foronda</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>MacWilliams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional communication in healthcare: An integrative review.</article-title>
            <source>Nurse Educ Pract</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>19</volume>
            <fpage>36</fpage>
            <page-range>36-40</page-range>
            <pub-id pub-id-type="pmid">27428690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Manhas</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Patient-reported outcome use in oncology: a systematic review of the impact on patient-clinician communication.</article-title>
            <source>Support Care Cancer</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-60</page-range>
            <pub-id pub-id-type="pmid">28849277</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19571.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abueg</surname>
                <given-names>KD</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional Management of Toxicities Related to Cancer Precision Medicine.</article-title>
            <source>Semin Oncol Nurs</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>376</fpage>
            <page-range>376-383</page-range>
            <pub-id pub-id-type="pmid">28927762</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
